Advances in the Treatment of Urothelial Carcinomas
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview of Practice Patterns in Urothelial Carcinoma By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.
EP. 2: How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma? By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
EP. 3: Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.
EP. 4: MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
EP. 5: Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
EP. 6: Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
EP. 7: Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.
EP. 8: Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.
EP. 9: Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257 By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
EP. 10: Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.
EP. 11: Novel Treatment Strategies in Muscle Invasive Bladder Cancer By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.
EP. 12: First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.
EP. 13: Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.
EP. 14: Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.
EP. 15: Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.
EP. 16: Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.
EP. 17: Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.
EP. 18: Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape By Shilpa Gupta, MD, Cleveland Clinic, Andrea B. Apolo, MD, National Cancer Institute, Petros Grivas MD, PhD, Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
